Company / Free Cash Flow
Entrada Therapeutics, Inc. Free Cash Flow History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$44.7M
FY2025
5-year range
-$96.7M / $134.2M
FY2023-FY2025
Trend
-133.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$97M to -$45M over the past 2 years.
Based on SEC 10-K filings.
-$45M in FY2025.
Improved from -$97M to -$45M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow decreased 133.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.03 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$44.7M | -133.3% |
| FY2024 | $134.2M | +238.8% |
| FY2023 | -$96.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026